2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/13/16Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors
SAN FRANCISCO, Dec. 13, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Julie Anne Smith to its board of directors. "We are delighted to welcome Julie to our board of directors," stated Matthew Patterson, President and Chief Executive Officer. "Julie is a seasoned biotech leader with a pro... 
Printer Friendly Version
11/29/16Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility
Milestone Establishes Audentes as a Leader in AAV Gene Therapy Manufacturing SAN FRANCISCO, Nov. 29, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has successfully initiated large-scale cGMP (current Good Manufacturing Practice) production runs in its new, state-of-the-art manufacturing facility. Ma... 
Printer Friendly Version
11/21/16Audentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference
SAN FRANCISCO, Nov. 21, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its plans to attend the Piper Jaffray 28th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on November 29-30, 2016.  Matthew R. Patterson, President and Chief Executive Officer, will participate on a ... 
Printer Friendly Version
11/10/16Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Completed Initial Public Offering of 5.675 Million Shares of Common Stock, Completed Large-Scale Engineering Runs at Its Internal Manufacturing Facility, Commenced Enrollment in the INCEPTUS Clinical Assessment Study of XLMTM SAN FRANCISCO, Nov. 10, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financi... 
Printer Friendly Version
09/21/16Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Sept. 21, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology September 28, 2016, 9:30 AM ET Lot... 
Printer Friendly Version
08/31/16Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Achievements Included Completion of IPO, Initiation of Large Scale Manufacturing Runs and Enrollment of First Patient in a Clinical Assessment Study of XLMTM SAN FRANCISCO, Aug. 31, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the quarter ended June 30, 2016 and provided an... 
Printer Friendly Version
08/17/16Audentes Therapeutics Announces First Patient Enrolled in the INCEPTUS Clinical Assessment Study of XLMTM
Study intended to serve as longitudinal baseline and within-patient control for ASPIRO, the planned Phase 1 / 2 study of AT132 for the treatment of XLMTM SAN FRANCISCO, Aug. 17, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported that the first patient has been enrolled in INCEPTUS, a prospective ... 
Printer Friendly Version
08/08/16Audentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
SAN FRANCISCO, Calif., Aug. 8, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 10:20 am ET. To access the live webcast of the Audentes presentation, p... 
Printer Friendly Version
07/19/16Audentes Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO, July 19, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Audentes. The shares are expected to begin trading on The NASDAQ Global Mark... 
Printer Friendly Version
05/04/16Audentes Therapeutics and the University of Pennsylvania Announce Collaboration to Develop AAV Gene Therapy for Severe Liver Disease
IND filing for AT342 for the Treatment of Crigler-Najjar Syndrome Expected in 2016 and Preliminary Data from a Phase 1/2 Clinical Trial Expected in 2017SAN FRANCISCO, CA – May 4, 2016 – Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases, today announced a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Penn... 
Printer Friendly Version
04/27/16Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
SAN FRANCISCO, CA – April 27, 2016 – Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients with serious, rare diseases, announced today that data related to its product candidate AT132 will be presented at the 19th Annual Meeting of the American Society of Gene and Cell Therapy to be held in Washington, D.C. on May 4-7th, 2016. The promising results from a long-term pre-clinical study of AT132 in a dog model of X-li... 
Printer Friendly Version
01/05/16Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors
SAN FRANCISCO, CA – January 5, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointment of Scott Morrison to its board of directors. Mr. Morrison will serve as chairman of the Audentes Therapeutics audit committee.“We are excited to have Scott join the Audentes team,” stated Matthew Patterson, President and Chief Executive Officer. “Scott b... 
Printer Friendly Version